Table 2.
Results for all participants tested from 0 to 12 months for colonisation with the targeted antimicrobial resistant organisms
| Proportion colonised (%) | ||||||
|---|---|---|---|---|---|---|
| Resistance phenotype | July 2012 f | October 2012 f | January 2013 f | May 2013 f | August 2013 f | Any time point |
| ESBL-EC a | 20/51 (39%) | 21/51 (41%)7 | 14/50 (28%) | 21/49 (43%)7 | 19/45 (42%)7 | 35/64 (55%) |
| ESBL - KP b | 0/51 (0%) | 2/51 (4%) | 0/50 (0%) | 2/49 (4%) | 2/45 (4%) | 5/64 (8%) |
| CPE c | 0/51 (0%) | 0/51 (0%) | 0/50 (0%) | 0/49 (0%) | 0/45 (0%) | 0/64 0%) |
| VRE d | 0/51 (0%) | 0/51 (0%) | 1/50 (2%) | 1/49 (2%) | 1/45 (2%) | 2/64 (3%) |
| MRSA e | 8/51 (16%) | 9/51 (18%) | 7/50 (14%) | 7/49 (14%) | 4/45 (9%) | 17/64 (27%) |
| Any of above | 24/51 (47%) | 25/51 (49%) | 17/50 (34%) | 23/49 (47%) | 20/45 (44%) | 39/64 (61%) |
aESBL-EC; Extended-spectrum beta-lactamase producing-Escherichia coli.
bESBL-KP; Extended-spectrum beta-lactamase-producing-Klebsiella pneumoniae.
cCPE; Carbapenemase-producing Enterobacteriaceae.
dVRE; Vancomycin-resistant enterococci.
eMRSA; Meticillin-resistant Staphylococcus aureus.
fNumber of participants tested at each interval varied, accounting for participants who died, withdrew from the study, or newly joined the study.
gOne resident had an ESBL-EC positive urine and rectal culture.